QWM
GPCR icon

Quadcap Wealth Management’s Structure Therapeutics GPCR Stock Holding History

Quadcap Wealth Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$410K Buy
7,635
+2,906
+61% +$129K 0.04% 301
2026
Q1 		$228K Sell
4,729
-2,754
-37% -$188K 0.03% 356
2025
Q4 		$355K Buy
+7,483
New +$306K 0.04% 301
2025
Q1 		– Sell
-7,851
Closed -$213K – 393
2024
Q4 		$213K Sell
7,851
-949
-11% -$33.7K 0.03% 352
2024
Q3 		$386K Sell
8,800
-135
-2% -$5.22K 0.06% 277
2024
Q2 		$351K Buy
8,935
+949
+12% +$39K 0.06% 285
2024
Q1 		$342K Buy
+7,986
New +$337K 0.08% 252

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Quadcap Wealth Management's GPCR Position: Q2 2026 in Review

Quadcap Wealth Management increased its Structure Therapeutics (GPCR) stake by 61% in Q2 2026, buying an estimated $129K and bringing the position to 7,635 shares worth $410K. The position accounts for 0.04% of the portfolio, ranked #301.

Quadcap Wealth Management first reported a position in GPCR in Q1 2024 and has held it in 7 quarters since. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Quadcap Wealth Management held 7,635 shares of Structure Therapeutics worth $410K as of Q2 2026.
  • Quadcap Wealth Management bought 2,906 Structure Therapeutics shares in Q2 2026, an estimated $129K.
  • Structure Therapeutics made up 0.04% of Quadcap Wealth Management's portfolio in Q2 2026, its #301 holding.
  • Quadcap Wealth Management first reported a position in Structure Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Quadcap Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.